Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Immunovia AB (publ)
  6. News
  7. Summary
    IMMNOV   SE0006091997

IMMUNOVIA AB (PUBL)

(IMMNOV)
  Report
Delayed Nasdaq Stockholm  -  11:24 2022-09-30 am EDT
33.58 SEK   -0.65%
09/26Centers for Medicare & Medicaid Services issues preliminary payment rate determination for Immunovia's IMMray PanCan-d test
AQ
09/26Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test
CI
09/19Immunovia AB(OM:IMMNOV) dropped from S&P Global BMI Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Immunovia AB Announces Executive Changes

06/02/2022 | 02:48am EDT

Immunovia announced that Philipp Mathieu has been named Chief Executive Officer and President effective immediately. Since January, Philipp has been acting Chief Executive Officer and President. Philipp Mathieu has extensive experience as an adviser on corporate strategy, M&A and capital markets transactions to healthcare and life sciences companies.

Most recently, Philipp was a Portfolio Manager and Advisor to a multinational family office. Previously, he was an investment banker focused in the Healthcare sector at Lazard and Lehman Brothers.


© S&P Capital IQ 2022
All news about IMMUNOVIA AB (PUBL)
09/26Centers for Medicare & Medicaid Services issues preliminary payment rate determination ..
AQ
09/26Immunovia AB Issues Preliminary Payment Rate Determination for IMMray PanCan-D Test
CI
09/19Immunovia AB(OM:IMMNOV) dropped from S&P Global BMI Index
CI
08/24Transcript : Immunovia AB, Q2 2022 Earnings Call, Aug 24, 2022
CI
08/24Immunovia Publishes Interim Report Jan-June 2022
AQ
08/24Immunovia AB Reports Earnings Results for the Second Quarter and Six Months Ended June ..
CI
08/23Immunovia to present at Gilmartin Group's Emerging Growth Company Showcase
AQ
08/22Invitation to Immunovia's Q2 presentation
AQ
08/11Immunovia, Inc. Issued Clinical and Public Health Laboratory License from California De..
AQ
08/11Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California ..
CI
More news
Financials
Sales 2022 3,50 M 0,32 M 0,32 M
Net income 2022 -195 M -17,6 M -17,6 M
Net cash 2022 64,0 M 5,76 M 5,76 M
P/E ratio 2022 -3,90x
Yield 2022 -
Capitalization 760 M 68,4 M 68,4 M
EV / Sales 2022 199x
EV / Sales 2023 7,56x
Nbr of Employees 64
Free-Float 63,4%
Chart IMMUNOVIA AB (PUBL)
Duration : Period :
Immunovia AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOVIA AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 33,58 SEK
Average target price 110,00 SEK
Spread / Average Target 228%
EPS Revisions
Managers and Directors
Philipp Mathieu President & Chief Executive Officer
Hans Liljenborg Finance Director
Karin Almqvist Liwendahl Chief Financial Officer
Karl Arne Krister Borrebaeck Chairman
Rolf Bertil Ehrnström Chief Scientific Officer
Sector and Competitors